Zenoxa Oral Suspension Banana contains Oxcarbazepine 300mg/5ml, an antiepileptic agent indicated for the management of partial seizures and generalized tonic-clonic seizures in adults and pediatric patients. Oxcarbazepine acts by stabilizing hyperexcited neuronal membranes, inhibiting repetitive neuronal firing, and decreasing propagation of synaptic impulses, primarily through modulation of voltage-sensitive sodium channels. The oral suspension formulation facilitates accurate dosing and ease of administration, particularly in pediatric and geriatric populations who may have difficulty swallowing tablets. The banana flavor enhances palatability, improving patient compliance. Zenoxa Oral Suspension is contraindicated in patients with hypersensitivity to oxcarbazepine or carbamazepine. Caution is advised in patients with a history of hyponatremia, hepatic or renal impairment, and those receiving concomitant medications that may interact pharmacokinetically or pharmacodynamically. Common adverse effects include dizziness, somnolence, headache, nausea, and hyponatremia. Regular monitoring of serum sodium levels is recommended, especially during the initial treatment phase. Dosage should be individualized based on clinical response and tolerability, with gradual titration to minimize adverse effects. Zenoxa Oral Suspension Banana should be used under medical supervision, with adherence to prescribed dosing schedules to optimize therapeutic outcomes and minimize risks.